Journal
CLINICAL TOXICOLOGY
Volume 56, Issue 3, Pages 226-228Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/15563650.2017.1355465
Keywords
Flibanserin; Addyi; hypoactive sexual desire disorder; seizure; piperazine; benzylpiperazine; trifluoromethylpiperazine
Categories
Ask authors/readers for more resources
Introduction: Flibanserin is a medication recently approved by the FDA for treatment of generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Its mechanism of action is not fully understood but is thought to modulate serotonin receptors and increase levels of norepinephrine and dopamine. While much is known about toxicity of other drugs which affect these systems, there is little information about toxicity of flibanserin at this time.Case: We present a case of a 2-year-old boy who ingested an estimated 600mg of his mother's flibanserin. Following ingestion, the child developed facial twitching and unresponsiveness to pain, concerning for seizure-like activity. In the emergency department (ED) he was found to have hypertension, mydriasis, slurred speech, and normal labs. He responded well to supportive care including administration of benzodiazepines. Shortly after admission to the hospital, his temperature increased to 38.4 degrees C. Toxicology testing revealed the presence of 1-(3-trifluoromethylphenyl)-piperazine (TFMPP), a flibanserin metabolite. TFMPP is a recreational drug used as an alternative to 3,4-methylenedioxymethamphetamine (more commonly known as MDMA or ecstasy).Discussion: This case highlights potential toxicity associated with ingestion of flibanserin.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available